Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
5.14
+0.21 (4.26%)
Bozor ochiq: Aug 12, 2026, 11:27 AM EDT
5.02
+0.09 (1.83%)
Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT
Vanda Pharmaceuticals Inc., biotexnologiya kompaniyasi bo'lib, dunyo bo'ylab yuqori darajada qondirilmagan tibbiy ehtiyojlarni qondirish uchun davolash usullarini ishlab chiqish va tijoratlashtirishga qaratilgan. Kompaniyaning tijorat portfeliga bipolyar I buzilishi bilan bog'liq maniyak yoki aralash epizodlarning o'tkir davolash va shizofreniyani davolash uchun Fanapt; 24-soatlik uyqu-uyg'onish buzilishlarini (non-24) va tungi uyqu buzilishlarini davolash uchun HETLIOZ; ko'p sklerozning qaytalanish shakllarini davolash uchun PONVORY; va harakatlanishdan kelib chiqqan qusishni oldini olish uchun NEREUSTM kiradi. Shuningdek, kompaniya shizofreniya va gipertenziyani davolash uchun uzoq muddat ta'sir qiluvchi in'ektsion (LAI) shakldagi Fanapt (iloperidone); bipolyar I buzilishi bilan bog'liq maniyak yoki aralash epizodlarning o'tkir davolash, shizofreniya va katta depressiv buzilishlarni davolash uchun BysantiTM (milsaperidone); jet lag buzilishini, uyqusizlikni, bolalardagi uyqusizlikni, uyqu fazasining kechikish sindromini va bolalardagi Non-24 ni davolash uchun HETLIOZ (tasimelteon); psoriaz va yarali kolitni davolash uchun PONVORY (ponesimod); va GLP-1 retseptorlari agonistlari tomonidan qo'zg'atilgan qusishni oldini olish, shuningdek, gastroparez va atopik dermatitni davolash uchun NEREUSTM (tradipitant)ni ishlab chiqadi. Bundan tashqari, kompaniyaning mahsulotlariga umumiy pustulyoz psoriazni davolash uchun IL-36R antagonist bo'lgan Imsidolimab; gematologik malignliklar va onixomikozni, shuningdek, bir nechta onkologik ko'rsatmalarni davolash uchun VTR-297; va ijtimoiy/ijro anksiyete va ruhiy kasalliklarni davolash uchun kichik molekulali alfa-7 nikotinik asetilxolin retseptorining qisman agonisti bo'lgan VQW-765 kiradi. Bundan tashqari, kompaniya kistik fibroz transmembran o'tkazuvchanlik regulyatori aktivatorlari va ingibitorlari; va antisense oligonukleotid molekulalarini ishlab chiqadi. Kompaniya 2002 yilda tashkil etilgan va Vashington, Kolumbiya okrugida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Mihael H. Polymeropoulos M.D. | Founder, President, CEO & Chairman of The Board |
| Mr. Christos Polymeropoulos M.D. | Senior Vice President & Medical Director |
| Mr. Daniel Patrick McGuire | Senior VP, General Counsel & Secretary |
| Mr. Gunther Birznieks | Senior Vice President of Business Development |
| Mr. Joakim Wijkstrom | Senior VP & Chief Marketing Officer |
| Mr. Kevin Patrick Moran | Senior VP, CFO & Treasurer |
| Mr. Scott L. Howell | Chief People Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-08-06 | 10-Q | vnda-20260630.htm |
| 2026-08-05 | 8-K | vnda-20260805.htm |
| 2026-06-05 | S-8 | vnda-20260605sx8.htm |
| 2026-06-05 | 8-K | vnda-20260604.htm |
| 2026-05-07 | 10-Q | vnda-20260331.htm |
| 2026-05-06 | 8-K | vnda-20260506.htm |
| 2026-04-24 | CORRESP | filename1.htm |
| 2026-04-23 | DEFA14A | defa14a-2026.htm |
| 2026-04-23 | DEF 14A | vnda-20260423.htm |
| 2026-04-23 | ARS | vnda1231202510k-ars.pdf |